Last 12 months
Inside the activity.
1 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 13 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC |
Sadler Jason DPres., International Markets
|
GrantCommon Stock, $.01 Par Value | 2,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004246 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,915 F1 · shares: These restricted stock units vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
Jones Nicole SEVP, General Counsel
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 12,946 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004239 · doc4.xml · derivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,946 Underlying: Common Stock, $.01 Par Value · 12,946 shares Expires 2029-02-27 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
Jones Nicole SEVP, General Counsel
|
GrantCommon Stock, $.01 Par Value | 3,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004239 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,448 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:24 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,116 | $0.00 Strike: $110.47 | $0.00 |
DisclosureSEC source: 0001225208-19-004249 · doc4.xml · derivative · entry 8 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 1,116 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents options that were automatically exercised immediately prior to their expiration. F6 · derivative.exercise_date: Stock option previously awarded pursuant to Express Scripts, Inc. 2011 Long-Term Incentive Plan. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:24 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 5,179 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004249 · doc4.xml · derivative · entry 7 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,179 Underlying: Common Stock, $.01 Par Value · 5,179 shares Expires 2029-02-27 F5 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:24 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,566 | $0.00 Strike: $110.47 | $0.00 |
DisclosureSEC source: 0001225208-19-004249 · doc4.xml · derivative · entry 6 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 12,566 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents options that were automatically exercised immediately prior to their expiration. F4 · derivative.exercise_date: Stock option previously awarded pursuant to Express Scripts, Inc. 2011 Long-Term Incentive Plan. Options vested in three equal annual installments on February 28, 2013, February 28, 2014, and February 28, 2015. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:24 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 9,135 | $180.72 | $1,650,877.20 |
DisclosureSEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 5 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,546 F2 · shares: Represents shares tendered to Company to cover payment of exercise price and tax liability due upon exercise of stock option. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:24 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 812 | $180.72 | $146,744.64 |
DisclosureSEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 4 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,681 F2 · shares: Represents shares tendered to Company to cover payment of exercise price and tax liability due upon exercise of stock option. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:24 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
Exercise / conversionCommon Stock, $.01 Par Value | 1,116 | $110.47 | $123,289.99 |
DisclosureSEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 3 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:24 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
GrantCommon Stock, $.01 Par Value | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,377 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:24 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
Exercise / conversionCommon Stock, $.01 Par Value | 12,566 | $110.47 | $1,388,227.59 |
DisclosureSEC source: 0001225208-19-004249 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC |
WENTWORTH TIMOTHY CPres, Exp Scrpts & Cigna Svcs
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 28,246 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004248 · doc4.xml · derivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,246 Underlying: Common Stock, $.01 Par Value · 28,246 shares Expires 2029-02-27 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC |
WENTWORTH TIMOTHY CPres, Exp Scrpts & Cigna Svcs
|
GrantCommon Stock, $.01 Par Value | 8,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004248 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,465 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC |
Triplett Michael WPresident, US Markets
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 8,945 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004247 · doc4.xml · derivative · entry 3 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,945 Underlying: Common Stock, $.01 Par Value · 8,945 shares Expires 2029-02-27 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC |
Triplett Michael WPresident, US Markets
|
GrantCommon Stock, $.01 Par Value | 2,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004247 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,488 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:21 UTC |
Agoglia Hoeltzel Mary TSVP Tax & Chief Acct. Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 2,354 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004237 · doc4.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,354 Underlying: Common Stock, $.01 Par Value · 2,354 shares Expires 2029-02-27 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:21 UTC |
Agoglia Hoeltzel Mary TSVP Tax & Chief Acct. Officer
|
GrantCommon Stock, $.01 Par Value | 682 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004237 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,317 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC |
Evanko Brian CPresident Government Business
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 8,286 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004245 · doc4.xml · derivative · entry 3 Evanko Brian C · CIK 0001722909 · President Government Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,286 Underlying: Common Stock, $.01 Par Value · 8,286 shares Expires 2029-02-27 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:23 UTC |
Evanko Brian CPresident Government Business
|
GrantCommon Stock, $.01 Par Value | 2,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004245 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · President Government Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,240 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
Manders Matthew GPresident, Strategy & Solution
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 18,360 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004244 · doc4.xml · derivative · entry 2 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,360 Underlying: Common Stock, $.01 Par Value · 18,360 shares Expires 2029-02-27 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
Manders Matthew GPresident, Strategy & Solution
|
GrantCommon Stock, $.01 Par Value | 5,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004244 · doc4.xml · nonDerivative · entry 1 Manders Matthew G · CIK 0001480601 · President, Strategy & Solution 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,093 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
BOXER MARK LEVP, Chief Information Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 5,885 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004242 · doc4.xml · derivative · entry 3 BOXER MARK L · CIK 0001238506 · EVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,885 Underlying: Common Stock, $.01 Par Value · 5,885 shares Expires 2029-02-27 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
BOXER MARK LEVP, Chief Information Officer
|
GrantCommon Stock, $.01 Par Value | 1,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004242 · doc4.xml · nonDerivative · entry 1 BOXER MARK L · CIK 0001238506 · EVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,070 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
Bacus Lisa REVP, Chief Marketing Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 3,578 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004241 · doc4.xml · derivative · entry 2 Bacus Lisa R · CIK 0001577243 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,578 Underlying: Common Stock, $.01 Par Value · 3,578 shares Expires 2029-02-27 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
Bacus Lisa REVP, Chief Marketing Officer
|
GrantCommon Stock, $.01 Par Value | 1,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004241 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,236 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
Cordani DavidDirector · President & CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 63,553 | $0.00 Strike: $183.44 | $0.00 |
DisclosureSEC source: 0001225208-19-004238 · doc4.xml · derivative · entry 3 Cordani David · CIK 0001318751 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,553 Underlying: Common Stock, $.01 Par Value · 63,553 shares Expires 2029-02-27 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:22 UTC |
Cordani DavidDirector · President & CEO
|
GrantCommon Stock, $.01 Par Value | 18,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004238 · doc4.xml · nonDerivative · entry 1 Cordani David · CIK 0001318751 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,405 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:01 UTC |
Agoglia Hoeltzel Mary TVP & Chief Accounting Officer
|
OtherCommon Stock, $.01 Par Value | 17.3026 | $196.17 | $3,394.20 |
DisclosureSEC source: 0001225208-19-003123 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · VP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Disclosed balance after: 484.7613 F1 · balance_after: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 22:32 UTC |
Palmer Eric PEVP, Chief Financial Officer
|
GrantPhantom Stock Units · Derivative | 780.7241 | $185.12 Strike: $0.00 | $144,527.65 |
DisclosureSEC source: 0001225208-19-002560 · doc4.xml · derivative · entry 1 Palmer Eric P · CIK 0001710190 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780.7241 Underlying: Common Stock, $.01 Par Value · 780.7241 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock represents the right to receive the cash value of one share of Cigna Common Stock. F2 · derivative.exercise_date: Shares of phantom stock are payable in cash in accordance with the terms of Cigna's Deferred Compensation Plan. The reporting person may transfer his phantom stock account into an alternative investment account. F2 · derivative.expiration_date: Shares of phantom stock are payable in cash in accordance with the terms of Cigna's Deferred Compensation Plan. The reporting person may transfer his phantom stock account into an alternative investment account. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:45 UTC |
Triplett Michael WPresident, US Markets
|
SaleCommon Stock, $.01 Par Value | 9,148 | $181.01 | $1,655,888.63 |
DisclosureSEC source: 0001225208-19-002462 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,898 Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 22:08 UTC |
PARTRIDGE JOHNDirector
|
SaleCommon Stock, $.01 Par Value | 1,000 | $184.43 | $184,426.70 |
DisclosureSEC source: 0001225208-19-002154 · doc4.xml · nonDerivative · entry 1 PARTRIDGE JOHN · CIK 0001319897 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,580 Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 00:06 UTC |
WENTWORTH TIMOTHY CPres, Exp Scrpts & Cigna Svcs
|
GrantCommon Stock, $.01 Par Value | 31,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-001830 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,287 Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 00:05 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
GrantCommon Stock, $.01 Par Value | 4,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-001829 · doc4.xml · nonDerivative · entry 1 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,311 F1 · balance_after: Total holdings were increased by one share of common stock due to a rounding error on the Form 4 report that was filed on December 26, 2018. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:06 UTC |
WENTWORTH TIMOTHY CPres, Exp Scrpts & Cigna Svcs
|
GrantPhantom Stock Units · Derivative | 731.2871 | $194.06 Strike: $0.00 | $141,913.57 |
DisclosureSEC source: 0001225208-19-001830 · doc4.xml · derivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878.2871 Underlying: Common Stock, $.01 Par Value · 731.2871 shares Expires not disclosed F2 · security: Phantom Stock Units credited under Express Scripts Executive Deferred Compensation Plan. F3 · derivative.exercise_price: Upon distribution, each Phantom Stock Unit converts to one share of Cigna Corporation Common Stock. F4 · derivative.exercise_date: Basic Company Credit by Cigna Corporation to Participant's account in the Express Scripts Executive Deferred Compensation Plan; the Basic Company Credit is fully vested once credited to the Participant's account. F4 · derivative.expiration_date: Basic Company Credit by Cigna Corporation to Participant's account in the Express Scripts Executive Deferred Compensation Plan; the Basic Company Credit is fully vested once credited to the Participant's account. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:05 UTC |
Miller Steven BEVP, Chief Clinical Officer
|
GrantPhantom Stock Units · Derivative | 154.6726 | $194.06 Strike: $0.00 | $30,015.76 |
DisclosureSEC source: 0001225208-19-001829 · doc4.xml · derivative · entry 2 Miller Steven B · CIK 0001599611 · EVP, Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118.6726 Underlying: Common Stock, $.01 Par Value · 154.6726 shares Expires not disclosed F2 · security: Phantom Stock Units credited under Express Scripts Executive Deferred Compensation Plan. F3 · derivative.exercise_price: Upon distribution, each Phantom Stock Unit converts to one share of Cigna Corporation Common Stock. F4 · derivative.exercise_date: Basic Company Credit by Cigna Corporation to Participant's account in the Express Scripts Executive Deferred Compensation Plan; the Basic Company Credit is fully vested once credited to the Participant's account. F4 · derivative.expiration_date: Basic Company Credit by Cigna Corporation to Participant's account in the Express Scripts Executive Deferred Compensation Plan; the Basic Company Credit is fully vested once credited to the Participant's account. Read SEC document |
| January 22, 2019 Filed Feb 6, 2019 00:06 UTC |
WENTWORTH TIMOTHY CPres, Exp Scrpts & Cigna Svcs
|
GiftCommon Stock, $.01 Par Value | 4,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-001830 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 42,338 Read SEC document |
| January 22, 2019 Filed Feb 6, 2019 00:06 UTC |
WENTWORTH TIMOTHY CPres, Exp Scrpts & Cigna Svcs
|
GiftCommon Stock, $.01 Par Value | 4,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-001830 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Pres, Exp Scrpts & Cigna Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,948 F1 · balance_after: Total holdings were decreased by one share of common stock due to a rounding error on the Form 4 report that was filed on December 26, 2018. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 19:20 UTC |
ROPER WILLIAM LDirector
|
GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · nonDerivative · entry 2 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 00:25 UTC |
Granger ElderDirector
|
GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008718 · doc1.xml · nonDerivative · entry 2 Granger Elder · CIK 0001625579 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,788 Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 00:21 UTC |
DeLaney William J IIIDirector
|
GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008712 · doc1.xml · nonDerivative · entry 2 DeLaney William J III · CIK 0001384151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,849 Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 00:13 UTC |
MAZZARELLA KATHLEEN MDirector
|
GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008696 · doc1.xml · nonDerivative · entry 2 MAZZARELLA KATHLEEN M · CIK 0001273233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801 Read SEC document |
| December 21, 2018 Filed Feb 8, 2019 17:56 UTC Amendment |
ROPER WILLIAM LDirector
|
GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-002851 · doc1.xml · nonDerivative · entry 2 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,367 Read SEC document |
| December 21, 2018 Filed Feb 8, 2019 22:55 UTC Amendment |
MAZZARELLA KATHLEEN MDirector
|
GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-002849 · doc1.xml · nonDerivative · entry 1 MAZZARELLA KATHLEEN M · CIK 0001273233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 F1 · balance_after: Prior to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), the reporting person held Express Scripts restricted stock units. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. F2 · balance_after: (continued from previous footnote) The Form 4 filed December 26, 2018 inadvertently included the conversion of those restricted stock units into shares of New Cigna Common Stock based on the merger consideration exchange ratio. This amendment is being filed to correct that administrative error. Read SEC document |
| December 21, 2018 Filed Feb 8, 2019 22:53 UTC Amendment |
Granger ElderDirector
|
GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-002847 · doc1.xml · nonDerivative · entry 2 Granger Elder · CIK 0001625579 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Read SEC document |
| December 21, 2018 Filed Feb 8, 2019 22:52 UTC Amendment |
DeLaney William J IIIDirector
|
GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-002845 · doc1.xml · nonDerivative · entry 2 DeLaney William J III · CIK 0001384151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,784 Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC |
ROPER WILLIAM LDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 3,844 | Not disclosed Strike: $126.32 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 9 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,844 Underlying: Common Stock, $0.01 Par Value · 3,844 shares Expires 2027-05-11 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC |
ROPER WILLIAM LDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 3,376 | Not disclosed Strike: $151.48 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 8 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,376 Underlying: Common Stock, $0.01 Par Value · 3,376 shares Expires 2026-05-04 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC |
ROPER WILLIAM LDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 2,691 | Not disclosed Strike: $175.09 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 7 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,691 Underlying: Common Stock, $0.01 Par Value · 2,691 shares Expires 2025-05-06 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC |
ROPER WILLIAM LDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 3,074 | Not disclosed Strike: $139.63 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 6 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,074 Underlying: Common Stock, $0.01 Par Value · 3,074 shares Expires 2021-05-07 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC |
ROPER WILLIAM LDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 2,819 | Not disclosed Strike: $128.24 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 5 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,819 Underlying: Common Stock, $0.01 Par Value · 2,819 shares Expires 2020-05-09 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.